Advertisement

Regression in Adolescents and Adults with Down Syndrome

  • Brian ChicoineEmail author
  • George Capone
Chapter

Abstract

There has been a growing number of clinical case reports of regression in adolescents and adults with Down syndrome who have shown unexpected and severe regression in cognitive and adaptive functioning, motor function, communication skills, and behavior. In this chapter, we call this adult regression syndrome. It most commonly affects people with Down syndrome in their teens and twenties and is associated with cognitive-executive impairment, social withdrawal, loss of functional language and previously acquired adaptive skills, lasting greater than 3 months. The differential diagnosis is extensive suggesting that the brains of individuals with Down syndrome are vulnerable to further impairment from a variety of underlying causes. Several of the most important diagnoses are discussed further. Prognosis is highly dependent on both the cause and the certainty of the diagnosis. Further study is needed to improve our understanding of adult regression syndrome.

Keywords

Adolescents with Down syndrome Adults with Down syndrome Adult regression syndrome Auto-immunity Catatonia Down syndrome 

References

  1. 1.
    Akahoshi K, Matsuda H, Funahashi M, Hanaoka T, Suzuki Y. Acute neuropsychiatric disorders in adolescents and young adults with Down syndrome: Japanese case reports. Neuropsychiatr Dis Treat. 2012;8:339–45.  https://doi.org/10.2147/NDT.S32767.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down’s syndrome: prevalence, management, and diabetic complications. Diabet Med. 1998;15:160–3.  https://doi.org/10.1002/(SICI)1096-9136(199802)15:2<160::AID-DIA537>3.0.CO;2-J.CrossRefPubMedGoogle Scholar
  3. 3.
    Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012;27:1460–90.  https://doi.org/10.1177/0883073812448838.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study. Diabetologia. 2006;49:1179–82.  https://doi.org/10.1007/s00125-006-0231-6.CrossRefGoogle Scholar
  5. 5.
    Bouziat R, Hinterleitner R, Brown JJ, Stencel-Baerenwald JE, Ikizler M, Mayassi T, Jabri B. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science. 2017;356:44–50.  https://doi.org/10.1126/science.aah5298.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Capone GT, Grados MA, Kaufmann WE, Bernard-Ripoll S, Jewell A. Down syndrome and comorbid autism-spectrum disorder: characterization using the aberrant behavior checklist. Am J Med Genet. 2005;134:373–80.  https://doi.org/10.1002/ajmg.a.30622.CrossRefPubMedGoogle Scholar
  7. 7.
    Capone GT, Goyal P, Ares W, Lannigan E. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet C Semin Med Genet. 2006;142:158–72.CrossRefGoogle Scholar
  8. 8.
    Capone G, Aidikoff J, Taylor K, Rykiel N. Adolescents and young adults with Down syndrome presenting to a medical clinic with depression: co-morbid obstructive sleep apnea. Am J Med Genet A. 2013;161:2188–96.CrossRefGoogle Scholar
  9. 9.
    Castillo H, Patterson B, Hickey F, Kinsman A, Howard JM, Mitchell T, Molloy CA. Difference in age at regression in children with autism with and without Down syndrome. J Dev Behav Pediatr. 2008;29:89–93.  https://doi.org/10.1097/DBP.0b013e318165c78d.CrossRefPubMedGoogle Scholar
  10. 10.
    Castro P, Zaman S, Holland A. Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatments. J Neurol. 2017;264:804–13.  https://doi.org/10.1007/s00415-016-8308-8.CrossRefPubMedGoogle Scholar
  11. 11.
    Daniels J. Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci. 2009;21:371–80.  https://doi.org/10.1176/appi.neuropsych.21.4.371.CrossRefPubMedGoogle Scholar
  12. 12.
    Devenny DA, Matthews A. Regression: atypical loss of attained functioning in children and adolescents with Down syndrome. In: Hodapp RM, editor. International review of research in developmental disabilities, vol. 41. Oxford: Academic Press; 2011. p. 233–64.CrossRefGoogle Scholar
  13. 13.
    Down Syndrome Medical Interest Group-USA Work Group on Regression. July 2017. https://www.dsmig-usa.org.
  14. 14.
    Fink M, Shorter E, Taylor MA. Catatonia is not schizophrenia: Kraepelin’s error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull. 2010;36:314–20.  https://doi.org/10.1093/schbul/sbp059.CrossRefPubMedGoogle Scholar
  15. 15.
    Francis A, Fink M, Appiani F, Bertelsen A, Bolwig TG, Braunig P, Caroff SN, Carroll BT, Cavanna AE, Cohen D, Cottencin O, Cuesta MJ, Daniels J, Dhossche D, Fricchione GL, Gazdag G, Ghaziuddin N, Healy D, Klein D, Kruger S, Lee JW, Mann SC, Mazurek M, McCall WV, McDaniel WW, Northoff G, Peralta V, Petrides G, Rosebush P, Rummans TA, Shorter E, Suzuki K, Thomas P, Vaiva G, Wachtel L. Catatonia in the diagnostic and statistical manual of mental disorders, fifth edition. J ECT. 2010;26:246–7.  https://doi.org/10.1097/YCT.0b013e3181fe28bd.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ghaziuddin M, Tsai LY, Ghaziuddin N. Autism in Down’s syndrome: presentation and diagnosis. J Intellect Disabil Res. 1992;36:449–56.CrossRefGoogle Scholar
  17. 17.
    Ghaziuddin N, Nassiri A, Miles JH. Catatonia in Down syndrome: a treatable cause of regression. Neuropsychiatr Dis Treat. 2015;11:941–9.  https://doi.org/10.2147/NDT.S77307.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Head E, Powell D, Gold BT, Schmitt FA. Alzheimer’s disease in Down syndrome. Eur J Neurogen Dis. 2012;1:353–64.Google Scholar
  19. 19.
    Hepburn S, Philofsky A, Fidler DJ, Rogers S. Autism symptoms in toddlers with Down syndrome: a descriptive study. J Appl Res Intellect Disabil. 2008;21:48–57.  https://doi.org/10.1111/j.1468-3148.2007.00368.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Hestnes A, Daniel SE, Lees AJ, Brun A. Down’s syndrome and Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:289.CrossRefGoogle Scholar
  21. 21.
    Jacobs J, Schwartz A, McDougle CJ, Skotko BG. Rapid clinical deterioration in an individual with Down syndrome. Am J Med Genet A. 2016;170:1899–902.  https://doi.org/10.1002/ajmg.a.37674.CrossRefPubMedGoogle Scholar
  22. 22.
    Kent L, Evans J, Paul M, Sharp M. Comorbidity of autistic spectrum disorders in children with Down syndrome. Dev Med Child Neurol. 1999;41:153–8.CrossRefGoogle Scholar
  23. 23.
    Kinik ST, Ozcay F, Varan B. Type I diabetes mellitus, Hashimoto’s thyroiditis and celiac disease in an adolescent with Down syndrome. Pediatr Int. 2006;48:433–5.  https://doi.org/10.1111/j.1442-200X.2006.02238.x.CrossRefPubMedGoogle Scholar
  24. 24.
    Kirkhart R, Ahuja N, Lee JW, Ramirez J, Talbert R, Faiz K, Ungvari GS, Thomas C, Carroll BT. The detection and measurement of catatonia. Psychiatry (Edgmont). 2007;4:52–6.Google Scholar
  25. 25.
    Krinsky-McHale SJ, Jenkins EC, Zigman WB, Silverman W. Ophthalmic disorders in adults with Down syndrome. Curr Gerontol Geriatr Res. 2012;2012:974253.  https://doi.org/10.1155/2012/974253.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kumar V, Rajadhyaksha M, Wortsman J. Celiac disease-associated autoimmune endocrinopathies. Clin Diagn Lab Immunol. 2001;8:678–85.  https://doi.org/10.1128/CDLI.8.4.678-685.2001.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol. 1989;46(8):849–53.CrossRefGoogle Scholar
  28. 28.
    Leroy A, Naudet F, Vaiva G, Francis A, Thomas P, Amad A. Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2017;  https://doi.org/10.1007/s00406-017-0819-5.CrossRefGoogle Scholar
  29. 29.
    Mann DM. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev. 1988;43:99–136.CrossRefGoogle Scholar
  30. 30.
    Mårild K, Stephansson O, Grahnquist L, Cnattingius S, Söderman G, Ludvigsson JF. Down syndrome is associated with elevated risk of celiac disease: a nationwide case-control study. J Pediatr. 2013;163:237–42.  https://doi.org/10.1016/j.jpeds.2012.12.087.CrossRefPubMedGoogle Scholar
  31. 31.
    Miles J. Catatonia as a cause of regression in Down syndrome. Presentation at the annual symposium of the Down Syndrome Medical Interest Group-USA, Sacramento, CA. 2017.Google Scholar
  32. 32.
    Mircher C, Cieuta-Walti C, Marey I, Rebillat AS, Cretu L, Milenko E, Conte M, Sturtz F, Rethore MO, Ravel A. Acute regression in young people with Down syndrome. Brain Sci. 2017;7:E57.  https://doi.org/10.3390/brainsci7060057.CrossRefPubMedGoogle Scholar
  33. 33.
    Moran JA, Rafii MS, Keller SM, Singh BK, Janicki MP, American Academy of Developmental Medicine and Dentistry, Rehabilitation Research and Training Center on Aging with Developmental Disabilities at University of Illinois at Chicago, American Association on Intellectual and Developmental Disabilities. The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin Proc. 2013;88:831–40.  https://doi.org/10.1016/j.mayocp.2013.04.024.CrossRefPubMedGoogle Scholar
  34. 34.
    Myers BA, Pueschel SM. Major depression in a small group of adults with Down syndrome. Res Dev Disabil. 1995;16:285–99.CrossRefGoogle Scholar
  35. 35.
    Padhy SK, Parakh P, Sridhar M. The catatonia conundrum: controversies and contradictions. Asian J Psychiatr. 2014;7:6–9.  https://doi.org/10.1016/j.ajp.2013.07.006.CrossRefPubMedGoogle Scholar
  36. 36.
    Pellegrini FP, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F, Mortara L, Accolla RS, Nespoli L. Down syndrome, autoimmunity and T regulatory cells. Clin Exp Immunol. 2012;169:238–43.  https://doi.org/10.1111/j.1365-2249.2012.04610.x.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Popova G, Paterson WF, Brown A, Donaldson MD. Hashimoto’s thyroiditis in Down’s syndrome: clinical presentation and evolution. Horm Res. 2008;70:278–84.  https://doi.org/10.1159/000157874.CrossRefPubMedGoogle Scholar
  38. 38.
    Prasher V. Disintegrative syndrome in young adults [Letter to the editor]. Irish J Psychol Med. 2002;19:101.CrossRefGoogle Scholar
  39. 39.
    Prasher VP, Sachdeva N, Tarrant N. Diagnosing dementia in adults with Down’s syndrome. Neurodegen Dis Manag. 2015;5:249–56.  https://doi.org/10.2217/nmt.15.8.CrossRefGoogle Scholar
  40. 40.
    Principi N, Benoli MG, Bianchini S, Esposito S. J Clin Virol. 2017;96:26–31.  https://doi.org/10.1016/j.jcv.2017.09.003.CrossRefPubMedGoogle Scholar
  41. 41.
    Rasmussen P, Borjesson O, Wentz E, Gillberg C. Autistic disorders in Down syndrome: background factors and clinical correlates. Dev Med Child Neurol. 2001;43:750–4.CrossRefGoogle Scholar
  42. 42.
    Rollin H. Personality in mongolism with special reference to the incidence of catatonic psychosis. Am J Ment Defic. 1946;51:219–37.PubMedGoogle Scholar
  43. 43.
    Sabbagh M, Edgin J. Clinical assessment of cognitive decline in adults with Down syndrome. Curr Alzheimer Res. 2016;13:30–4.CrossRefGoogle Scholar
  44. 44.
    Shorter E. Making childhood catatonia visible, separate from competing diagnoses (Comment). Acta Psychiatr Scand. 2012;125:3–10.  https://doi.org/10.1111/j.1600-0447.2011.01788.x.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Stein DS, Munir KM, Karweck AJ, Davidson EJ, Stein MT. Developmental regression, depression, and psychosocial stress in an adolescent with Down syndrome. J Dev Behav Pediatr. 2013;34:216–8.  https://doi.org/10.1097/DBP.0b013e31828b2b42.CrossRefPubMedGoogle Scholar
  46. 46.
    Tyrrell J, Cosgrave M, McCarron M, McPherson J, Calvert J, Kelly A, McLaughlin M, Gill M, Lawlor BA. Dementia in people with Down’s syndrome. Int J Geriatr Psychiatry. 2001;16:1168–74.CrossRefGoogle Scholar
  47. 47.
    Vieregge P, Ziemens G, Piosinski A, Freudenberg M, Kömpf D. Parkinsonian features in advanced Down’s syndrome. J Neural Transm Suppl. 1991;33:119–24.PubMedGoogle Scholar
  48. 48.
    Warren AC, Holroyd S, Folstein FM. Major depression in Down’s syndrome. Br J Psychiatry. 1989;155:202–5.CrossRefGoogle Scholar
  49. 49.
    Wisniewski KE, French JH, Rosen JF, Kozlowski PB, Tenner M, Wisniewski HM. Basal ganglia calcification (BGC) in Down’s syndrome (DS) – Another manifestation of premature aging. Ann N Y Acad Sci. 1982;396:179–89.CrossRefGoogle Scholar
  50. 50.
    Worley G, Crissman BG, Cadogan E, Milleson C, Adkins DW, Kishnani PS. Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome. J Child Neurol. 2015;30:1147–52.  https://doi.org/10.1177/0883073814554654.CrossRefPubMedGoogle Scholar
  51. 51.
    Zigman WB, Lott IT. Alzheimer’s disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev. 2007;13:237–46.  https://doi.org/10.1002/mrdd.20163.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Advocate Medical GroupAdult Down Syndrome CenterPark RidgeUSA
  2. 2.Faculty, Family Medicine ResidencyAdvocate Lutheran General HospitalPark RidgeUSA
  3. 3.PediatricsJohns Hopkins School of MedicineBaltimoreUSA
  4. 4.Down Syndrome Clinic & Research CenterKennedy Krieger InstituteBaltimoreUSA

Personalised recommendations